BioSpace News Archive

AdaptHealth Corp. announced today financial results for the first quarter ended March 31, 2023.

AdaptHealth Corp. announced today that Stephen Griggs will step down as Chief Executive Officer by mutual agreement with the Board of Directors, effective June 30, 2023.

Fusion Pharmaceuticals Inc. today announced that the Company will participate in a fireside chat presentation at the Guggenheim Healthcare Talks Radiopharmaceuticals Day on Monday, May 15, 2023.

ProQR Therapeutics NV. announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, May 7-10, 2023 in San Diego, CA, USA.

Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events on May-June.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, provides a summary of corporate updates and reports first quarter 2023 financial results.

Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Phathom Pharmaceuticals, Inc. announced new data from two post-hoc analyses presented in poster presentations at Digestive Disease Week® 2023, held May 6-9 in person in Chicago, IL and virtually.

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6.

Catalyst Pharmaceuticals, Inc. reported that it recently concluded a Type C meeting with the U.S. Food and Drug Administration regarding its plans to file a supplemental New Drug Application to increase the maximum daily dosage of FIRDAPSE® from 80mg to 100mg for the treatment of Lambert Eaton myasthenic syndrome.